Cite

    Achtnichts, L., Chan, A., Czaplinski, A., Derfuss, T., Du Pasquier, R., Findling, O., Gobbi, C., Hoepner, R., Kamber, N., Kamm, C., Kuhle, J., Lalive, P., Lutterotti, A., Martin, R., Müller, S., Papadopoulou, A., Pot, C., Salmen, A., Schippling, S., Zecca, C., & ,  (2019). specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clinical and translational neuroscience, 3(1), . http://access.bl.uk/ark:/81055/vdc_100089692123.0x000003